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ABSTRACT
Insulin-like growth factor 1 (IGF-1) is a mitogen which plays a key role in regulating cell proliferation, differentiation, and 
apoptosis. It belongs to the family of proteins also composed of insulin-like growth factor 2 (IGF-2), two types of membrane 
receptors (IGF-1R and IGF-2R), 6 binding proteins (IGFBP 1–6), hydrolyzing proteases, and reactive molecules binding 
proteins, which regulate the activity of growth factors. Disturbances in the functioning of IGFBP/IGF/1GF1R can lead to 
induction of carcinogenesis, which has been demonstrated in breast, prostate or colon cancers. Findings evaluating the 
role of IGF-1 in endometrial cancer biology are ambiguous and contradictory. Therefore, in the present study, we analyzed 
the role of IGF-1 in the process of carcinogenesis of endometrial cancer, based on the available literature. 
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INTRODUCTION
Insulin-like growth factor-1 (IGF-1), also known as somat-
omedin 1, is a mitogen which plays a pivotal role in regulat-
ing cell proliferation, differentiation, and apoptosis. IGF-1 is 
a member of a protein family which also includes insulin-like 
growth factor 2 (IGF-2), two types of membrane receptors 
(IGF-1R and IGF-2R), 6 binding proteins (IGFBP 1–6), hy-
drolyzing proteases, and other reactive molecules binding 
proteins which regulate the activity of growth factors [1]. 
Disturbances in the functioning of the IGFBP/IGF/1GF1R 
system may lead to the induction of carcinogenesis, which 
has been demonstrated in various types of malignancies, i.e. 
breast, prostate, or colon cancer. Both, increased activity of 
the IGF-1/IGF-1R complex and lowered IGF-BP expression 
have been mentioned among the promoting factors for 
neoplastic processes [2]. IGF-1 is believed to exert its mito-
genic effect on various cells by stimulating their proliferation 
and inhibiting their apoptosis via endocrine, paracrine and 
autocrine mechanisms [1]. Results of various studies which 
evaluated the role of IGF-1 in the biology of endometrial 
cancer (EC) are ambiguous and conflicting.
PHYSIOLOGICAL FUNCTION OF IGF-1
IGF-1 is predominantly produced by hepatocytes as a re-
sponse to growth hormone (GH) activity and released to the 
serum of peripheral circulation blood. GH/IGF-1 coopera-
tion is the main regulator of postnatal growth of the body, 
whereas IGF-2 plays a vital role during fetal development, and 
its synthesis is independent of GH. Insulin-like growth factors 
may also be synthesized de novo in the cells of various tissues 
(ovary, endometrium, breast, lung), where — being mitogenic 
factors — they participate in cellular growth processes and 
elicit anabolic effects. The primary role of IGF-1 consists in 
promoting cell and tissue growth and division [3–5]. The lit-
erature offers a significant amount of evidence that molecules 
from the insulin-like growth factors participate in proliferation 
and differentiation of normal endometrial cells, as well as 
embryo implantation. Various studies have demonstrated the 
presence of IGF-1, IGF-1, and all 6 IGFBP proteins in the endo-
metrium during a normal menstrual cycle [6]. IGF-1 circulates 
in blood either free or bound to low- or high-IGF affinity 
binding proteins. Six IGF-1 binding proteins (from IGFBP-1 to 
IGFBP-6) have been identified so far. Over 90% of the circulat-
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cells, which is induced by estrogens via stimulation of the 
local synthesis of 17β-hydroxysteroid dehydrogenase and 
estrogen sulfotransferase. As a result of their expression, E2 is 
converted to a less active estrone (E1) and estrone sulfates, 
which are quickly expelled from the cells and the body. Ad-
ditionally, as a result of progesterone activity, the synthesis 
of the IGF-1 binding protein (IGFBP-1), which blocks IGF-1 ac-
tivity in the endometrium by controlling IGF-1 availability 
for its cellular receptors, is stimulated. Estrogen-induced 
production of IGF-1 molecule, in the absence of IGFBP-1 syn-
thesis which depends on progesterone expression, results 
in abnormal proliferation of endometrial cells [7, 10]. Recent 
reports in the literature have confirmed a correlation be-
tween EC and insulin resistance, hyperinsulinemia, and type 
II diabetes, which frequently constitute direct consequences 
of obesity. Insulin is believed to exert mitogenic effects on 
various cell types, especially cancerous cells, as a result of 
binding to a receptor or via other, non-receptor mechanisms, 
e.g. changing expression of IGF-1 and its binding proteins, 
or blocking of antiproliferative activity of progesterone. In-
sulin has been shown to stimulate mitogenic processes also 
by suppressing IGFBP-1 expression. Hyperinsulinemia may 
lead to lowered IGFBP-1 expression, even in the presence 
of progesterone, which probably results in a blockage of its 
protective activity [11].
IGF-1 EXPRESSION IN TUMOR CELLS AND 
RESULTS OF IN VITRO STUDIES
The results of in vitro studies demonstrate that IGF-1 par-
ticipates in the process of EC carcinogenesis, both by induc-
ing IGF-1 is bound to IGFBP-3 and ALS (acid-labile subunit), 
resulting in the formation of a 150 kDa molecular mass com-
plex. The remaining part forms complexes with other proteins 
and less than 1% is unbound, which constitutes the active 
form of IGF-1. The effect of IGF-1 on cells of various tissues 
is executed via its binding to a specific receptor. There are 
two types of receptors which demonstrate affinity to IGF-1, 
namely IGF-1R and IGF-2R. However, IGF-2R binds IGF-1 to 
a lesser degree as compared to IGF-1R, thus revealing higher 
affinity to IGF-2 [1].
HYPOTHETICAL ROLE OF IGF-1 IN THE 
BIOLOGY OF ENDOMETRIAL CANCER
Research on the role of IGF-1 in the biology of endo-
metrial cancer was initiated on the basis of a hypothesis 
which had its roots in the correlation between endometrial 
cancer and the following conditions: obesity, type II diabe-
tes, and the mitogenic effect of estrogens on the endome-
trium. Type 1, whose development depends on abnormal 
stimulation of the endometrium by endogenous as well as 
exogenous estrogens, accounts for a significant number of 
sporadic EC cases [7]. Studies have demonstrated that es-
trogens (mainly E2) stimulate cell proliferation by inducing 
autocrine IGF-1 synthesis and expression of IGF-1 receptor 
in the uterus [8]. Additionally, IGF-1 encoding gene has been 
detected to undergo expression mainly in the follicular phase 
and early luteal phase of a menstrual cycle [9, 7]. Activa-
tion of the mitogenic effect of IGF-1 on the endometrium 
is the consequence of E2-dependent local production of 
IGF-1. Progesterone counteracts proliferation of endometrial 
Table 1. IGF-1 — in vitro findings
Parameter Cell population Experiment Result of the experiment Role  in carcinogenesis? Ref.
IGF-1 HEC-1B IGF-1 incubation with HEC-1B KCC induction
KCC 1 expression Yes [12]
mRNA:
IGF-1
IGF-1R
RL95-2, KLE, 
HEC, ISH
Evaluation of IGF-1 synthesis in 
the cells
Evaluation of mRNA expression:
IGF-1
IGF-1R
aIR3 incubation with the cells 
Autocrine IGF-1 synthesis
Autocrine stimulation of the cells by IGF-1
DNA synthesis induction in response to aIR3 Yes [13]
IGF-1 HEC-1A, KLE IGF-1 incubation with HEC-1A 
and KLE
Induced mitogenic activity of the cells Yes [14]
IGF-1
E2
ISH (ER+) E2 incubation with ISH (ER+)
Evaluation of IGF-1 activity after 
cell incubation with E2
IGF-1 incubation with ISH (ER+)
Incubation with E2: ® induction of cell 
proliferation ® induction IGF-1 secretion
Incubation with IGF-1 ® induction of cell 
proliferation
Yes [15]
IGF-1
VEGF
HEC-1A (ER–) IGF-1 incubation with HEC-1A Incubation with IGF-1 ® − mRNA VEGF 
activity Yes [22]
IGF-1
IGF-1R
IGFBPs
ISH, MCF-7 Cell incubation with tamoxifen −ISH proliferation
Induction of IGF-1R phosphorylation Yes [26]
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an experimental study on estrogen receptor-negative EC 
cells in order to assess IGF-1 role in the process of tumor 
neoangiogenesis. They found a dose- and time-dependent 
increase in VEGF mRNA expression, and an increased con-
centration of its protein product after 24 and 48 hour-incu-
bation of the HEC-1A cell line with exogenous IGF-1. These 
authors suggested that estrogen-dependent activation of 
the IGF-1 autocrine loop may result in tumor growth by 
stimulating the process of neoangiogenesis [22]. The pres-
ence of IGF-1R receptors were demonstrated both, in EC 
tissues and healthy endometrium (Table 2) [20, 23, 24]. 
Regardless, statistically significantly higher receptor bind-
ing affinity was found in EC tissues as compared to healthy 
endometrium. Also, IGF-1R binding affinity was proven to 
increase in response to decreasing tumor differentiation [23, 
25]. Additionally, tamoxifen, which is used in breast cancer 
therapy and which is a risk factor for the development of 
EC, has been demonstrated to lead to EC cell proliferation 
by inducing IGF-1R phosphorylation [26]. Furthermore, 
a dysregulation of genes encoding the components of the 
IGF-1 autocrine system and the ER receptor in the endome-
trium was also detected, which in consequence might lead 
to the development of EC [27]. 
On the other hand, Soufla et al., in a study of 30 postop-
erative EC preparations and 30 normal endometrial samples 
from the same patients, found no statistically significant 
differences in the mRNA IGF-1 transcription levels in both 
groups. On further analysis, these authors detected both, 
overexpression and lowered mRNA IGF-1 expression (39% 
ing proliferation of tumor cells and stimulating the process 
of neo-angiogenesis (Table 1) [12–15]. However, the results 
of in vivo studies are not as unambiguous (Table 2) [16–21].
Studies on the population of HEC-1B cells of EC revealed 
that induction of KCl-cotransport (KCC) is the result of 
IGF-1 activity. Also, IGF-1 was found to lead to KCC 1 expres-
sion, which affects tumor invasion ability [12]. Reynolds et al., 
in their study of EC cells (RL95-2, KLE, HEC, ISH), detected the 
presence of autocrine IGF-1 synthesis and mRNA IGF-1 and 
IGF 1R expression in all cell populations. Inhibition of DNA 
synthesis in response to cell incubation with IGF-1 recep-
tor-blocking antibody (aIR3) was observed in three cell lines 
(HEC 1A, KLE, ISH). These authors found autocrine stimula-
tion of EC cells by IGF-1 in three out of four populations of 
the investigated cells [13]. Pear et al., noted induction of 
time-dependent mitogenic activity of EC cells as a result of 
incubation of the cell populations (HEC 1A and KLE) with 
exogenous IGF-1. IGF-1 was found to play a regulatory role 
in the processes of EC cell growth. The authors postulated 
IGF-1 to mediate in estrogen-dependent proliferation of EC 
cells [14]. Kashima et al., in their study on EC cell popula-
tion (ISH) expressing ER, concluded that dose-dependent 
E2-induced proliferation of the cancerous cells occurs via the 
MAPK3/1 signaling pathway as a result of autocrine stimu-
lation of IGF-1. They also analyzed EC tissues and normal 
endometrial samples and reported MAPK3/1 expression and 
phosphorylation both, in tumor samples and healthy endo-
metrium, although MAPK3/1 expression was statistically 
significantly higher in EC cells [15]. Bermont et al., conducted 
Table 2. IGF-1 — tumor tissue expression
No. of samples Parameter Expression in EC tissues Additional information Ref.
26 — total IGF-1R « −IGF-1R binding affinity in tumor tissues [23]
59 — EC
10 — EH
7 — NE
IGF-1R
IGF-1
IGF-2R
−
− * [20]
152 — VM
(7 — EC)
63 — NT
IGF-1R − * [24]
30 — EC
30— NE mRNA IGF-1
− * [16]
15 — EC
45 — NE IGF-1
« * [17]
30 — EC
30 — NE
mRNA IGF-1
IGF-1 (p)
IGF-1R (p)
¯
«
«
* [21]
11 — EC
42 — NE
mRNA IGF-1R
mRNA IGF-1
−
−type I EC
¯type II EC
* [18]
13 — EC
10 — NE IGF-1 −EC cell proliferation
Inc. of IGF-1 with cells from the 
investigated samples was performed [19]
«the same in cell tissues and normal healthy endometrial samples, −increased, ¯lowered, EC — endometrial cancer, EH — endometrial hyperplasia,  
inc. — incubation; NE — normal endometrium, VM — various malignancies, NT — normal tissues, (p) — protein product
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and 56% of the cases) in tumor tissues as compared to 
the transcript level of that factor in normal healthy endo-
metrium. Regardless, they emphasize that the presence 
of mRNA IGF-1 overexpression constitutes an important 
element in the oncogenesis of EC because it is associated 
with the process of tumor neoangiogenesis [16]. Toole et 
al., observed lowered IGF-1, ERa, ERb, and PR (progesterone 
receptor) expression in EC tissues as compared to healthy 
endometrial samples [17]. Maiorano et al., in a study of 
postoperative EC preparations and healthy endometrial 
samples, found a lowered mRNA IGF-1 expression in tumor 
cells as compared to healthy tissues. In turn, the level of 
IGF-1 and IGF-1R protein products, measured by immuno-
histochemistry, was the same in tumor cells and healthy 
endometrium. These authors postulate that perhaps the 
IGF-1 system is not directly involved in the carcinogenesis of 
EC [21]. Roy et al., reported mRNA IGF-1R overexpression in 
all of the investigated EC tissues, whereas increased mRNA 
IGF-1 was detected only in cancers developing on the basis 
of an endometrial hyperplasia with atypia — type 1 EC. 
Lowered mRNA IGF-1 expression was observed in type 2 EC. 
Thus, these authors postulated the existence of two different 
mechanisms which activate IGF-1R in endometrial cancer: 
ligand-dependent in type 1 EC and ligand-independent in 
type 2 EC [18]. Reynolds et al., in their study of 13 EC prepa-
rations and 10 healthy endometrium samples, found that 
incubation of tumor tissues with IGF-1 results in higher EC 
cell proliferation. Interestingly, these authors observed that 
tissue proliferation of healthy endometrium is inhibited by 
IGF-1, EGF and TGF-alfa, and stimulated by cell incubation 
with Ab528 and α IR3 antibodies. The situation was reversed 
in case of EC cells. Based on their findings, these authors 
claimed the existence of a different, growth factor-depen-
dent mechanism of tumor cell and heathy endometrium 
proliferation [19]. Pavelić et al., observed an increased IGF-1, 
IGF-1R, and IGF-2R expression in EC tissues, especially in 
FIGO stage III and IV, as compared to healthy endometrium, 
and endometrial hyperplasia with atypia. They found that 
specific inhibition of IGF-1R, and IGF-2R activity resulted in 
inhibition of tumor cell proliferation. They implied that the 
local IGF-1 autocrine loop may play an important role in 
tumor progression [20].
SERUM IGF-1 AND ENDOMETRIAL CANCER
Researchers, inspired by the results of EC cell and tissue 
tests, started to investigate serum IGF-1 in women with 
endometrial cancer. However, these studies are scarce and 
the results remain inconsistent (Table 3) [10, 28–35]. 
Table 3. Serum IGF-1 concentration
No. of patients IGF-1 concentration Additional information Study oversight Ref.
166 — EC
315 — controls
«
Detailed 
Prospective study * [10]
288 — EC
392 — controls
« Detailed analysis * [29]
73 — EC
108 — controls
« Detailed analysis * [28]
174 — EC
136 — controls
« Detailed analysis * [30]
692 — EC
1723 — controls *
No link between IGF-1 gene 
polymorphism and risk for EC * [36]
32 — EC
18 — controls 
¯
Impaired glucose tolerance and 
hyperinsulinemia in EC women might 
have affected the results
CVD not included [32]
250 — EC
465 — controls
¯
−insulin levels in EC women might have 
affected the results CVD not included [51]
84 — EC
84 — controls
¯ * CVD not included [33]
56 — EC
40 — controls
¯ * CVD, impaired glucose tolerance, diabetes not included [31]
24 — EC
12 — EH with atypia
31 — EH without atypia
52 — controls (2 groups)
− * CVD, HRT, HC not included [35]
18 — EC
8 — controls
− * CVD not included [48]
«the same in cell tissues and normal healthy endometrial samples, −increased, ¯lowered, EC — endometrial cancer, EH — endometrial hyperplasia,  
CVD — cardiovascular diseases, HC — hormonal contraception, HRT — hormone replacement therapy
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Four studies found no association between serum 
IGF-1 and EC biology [10, 28–30]. Lukanova et al., in a mul-
ti-center prospective study in 481 women (166 — study 
group, 315 — controls), reported no link between the risk 
for EC and serum IGF-1 levels. They found no statistically 
significant differences between serum IGF-1 concentra-
tion and EC as compared to healthy women, regardless 
of their menopausal status at the time of blood collection 
(most women were postmenopausal at the time of test-
ing) [10]. Three other authors, in detailed analyses of large 
groups of patients, also found no statistically significant 
differences between serum IGF-1 concentration of women 
with EC as compared to healthy controls, or an association 
between that parameter and the risk for EC [28–30]. McGrath 
et al., in a large multi-center study including 2014 subjects 
(692 — women with EC, 1723 — controls) found no statisti-
cally significant correlation between IGF-1 gene polymor-
phism and the risk for EC. These authors imply that genetic 
variability in IGF-1 has no effect on the occurrence of EC [36].
Importantly, serum IGF-1 is synthesized mainly in the 
liver, and its level is affected by numerous endogenous 
— genetic predispositions, and exogenous factors — diet, 
physical exercise, medication use, including HRT, BMI, chron-
ic disease (DM, cardiovascular and other conditions), as well 
as age [37–47]. Authors of the abovementioned publications 
adjusted their results to the factors which might potentially 
affect the results of their analyses. Also, the studies took into 
account the menopausal status of the study participants 
as the analysis of serum IGF-1 levels in women with breast 
and ovarian cancers demonstrated a correlation between 
elevated serum IGF-1 levels and the risk for developing 
these cancers only in young patients, i.e. < 55 years of age, 
while no such association was found for postmenopausal 
women [48–50]. 
Some studies detected statistically significantly lower or 
higher serum IGF-1 levels in women with EC as compared 
to healthy controls [31–35, 51]. 
Four teams found statistically significantly lower 
IGF-1 levels in subjects with EC as compared to healthy 
women [31–35, 51], but they did not account for the possibil-
ity of cardiovascular diseases in the investigated populations 
(common in older, postmenopausal patients), what might 
be a serious study limitation due to a proven link between 
lowered serum IGF-1 level and these pathologies [40, 42].
Additionally, Rutanen et al., in their study on total serum 
IGF-1 level, found a statistically significantly higher inci-
dence of impaired glucose tolerance and hyperinsulinemia 
in women with EC as compared to controls, which — even 
according to these authors — might have affected the find-
ings of the study [32]. Gunter et al., also reported elevated 
serum insulin levels in patients at higher risk for developing 
EC cancer, which also might have influenced the final results 
of their analysis [51]. Studies indicate lowered serum total 
IGF-1 levels in women with hyperinsulinemia and impaired 
glucose tolerance [43, 44]. Serum free IGF-1 levels in women 
with type II diabetes are statistically significantly higher as 
compared to healthy populations [44]. 
The study by Baloglu et al., generated particularly inter-
esting results as these authors not only did not observe low-
er serum total IGF-1 levels in women with EC as compared 
to controls, but also noted decreased concentrations of that 
factor as the disease progressed [serum free IGF-1 levels 
were lower in women with myometrial infiltration (24 cases) 
as compared to infiltration-free women (32 cases)]. The 
results were surprising even for the authors, who stated 
they might have reflected disturbances in the functioning 
of the autocrine IGF-1 system in the uterus [31]. However, 
Lukanova is of the opinion that the locally produced IGF-1, 
whose synthesis is dominated by estrogens, participates in 
tumor biology, and serum IGF-1 level produced mainly in 
the liver as a response to GH activity is not a good marker of 
autocrine IGF-1 synthesis in the endometrium [10]. Besides, 
numerous factors affect the levels of serum IGF-1, including 
cardiovascular diseases, impaired glucose tolerance, elevat-
ed insulin levels, which often precede symptomatic diabetes 
type II, and that was not taken into consideration by these 
authors. Therefore, it remains unclear whether the obtained 
results indeed reflect the lowering IGF-1 level as the disease 
progresses, or whether they are caused by other reasons. The 
main limitation of the study by Baloglu et al., was the fact 
that they did not include patients with advanced-stage EC 
in their analysis, so the question whether the tendency for 
the serum IGF-1 level to drop would also be confirmed in 
more advanced disease, or disappear altogether, remains 
unanswered. Moreover, bearing in mind that most studies 
have confirmed the role of local IGF-1 loop in the biology of 
EC, the inverse correlation between serum IGF-1 level and 
disease advancement is unlikely to result from the process 
of endometrial carcinogenesis.
Two teams observed elevated serum IGF-1 levels in EC 
women as compared to controls [34, 35]. Waksmański et al., 
noted statistically significantly higher serum IGF-1 levels 
in women with EC and hyperplasia with atypia as com-
pared to patients with normal endometrium. However, 
these authors failed to consider the possibility of HRT or 
hormonal contraceptive use, or the existence of cardiovas-
cular diseases, which might have significantly affected the 
obtained results. That oversight questions the reliability 
of their findings [35]. Various authors have demonstrated 
that oral HRT leads to statistically significant decrease in 
serum IGF-1 levels, probably as a result of direct inhibition 
of its synthesis in the liver by the orally ingested estrogen 
[47]. Similarly to Waksmański et al., Ayabe et al., reported 
statistically significantly higher serum IGF-1 levels in post-
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menopausal Japanese women with EC (18 cases) as com-
pared to controls (8 cases). They did not observe statistically 
significant differences in IGF-1 levels among premenopau-
sal women with EC ac compared to controls (5 — study 
group, 19 — controls). However, they did not take into ac-
count the possibility of coexisting cardiovascular diseases, 
and the sample size was particularly small. Therefore, their 
study may not constitute a reliable proof for undisputed 
role of serum IGF-1 in the biology of EC. Furthermore, as 
was suggested by the authors themselves, higher serum 
IGF-1 levels in postmenopausal Japanese women with EC 
might have been the result of varying parameter values 
between different races [48]. Several studies have reported 
that serum IGF-1 levels may be determined by ethnicity [52]. 
The majority of the abovementioned studies investigated 
Caucasian women, and only the study by Gunter et al., in-
cluded 24 Asian subjects (7 — study group, 17 — controls) 
out of 715 all participants, although these authors did not 
mention any differences in IGF-1 concentration depending 
on the race [51]. Moreover, there is no consensus among 
researchers as to whether differences in serum IGF- levels 
are dependent on ethnicity [52]. 
CONCLUSIONS
On the basis of the abovementioned analysis of the 
literature, it seems safe to conclude that serum IGF-1 most 
probably does not participate in the process of endometrial 
carcinogenesis. The IGF-1 autocrine loop, which is present 
in the uterus, is believed to play a more significant role. 
Endometrial cancer affects mainly older, postmenopausal 
women, which might be an analogy to ovarian and breast 
cancers where, in case of postmenopausal patients, local 
IGF-1 system, rather than the factor present in the serum 
of the peripheral circulation, plays a role in tumor biology. 
Hypothetically, one cannot exclude the possibility that some 
women with EC present elevated serum IGF-1 levels, de facto 
resulting from the disease, as compared to normal healthy 
women, in which case that factor may participate, together 
with locally produced IGF-1, in the process of tumor onco-
genesis. The presence of low serum IGF-1 concentration in 
EC women as compared to controls, which is supposed to 
result from the neoplastic process and show a dysregulation 
of IGF-1 system functioning in the uterus, seems to be rather 
unlikely, especially taking into account tumor biology, as 
well as the results of various studies which demonstrate the 
mitogenic effect of that factor on EC cells. On the other hand, 
some in vivo studies of EC tissue preparations dismissed the 
possibility that insulin-like growth factor 1 plays a significant 
role in tumor biology. Thus, it is possible that neither serum 
IGF-1 nor local autocrine system, which is involved in the 
physiological processes of normal healthy endometrium, 
participate in the oncogenesis of endometrial cancer.
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